Last update Feb. 19, 2019

G03GA02

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Human Menopausal Gonadotrophin (HMG) is a natural hormone present in the urine of menopausal women which has the activity of follicle stimulating hormone (FSH) and luteinizing hormone (LH).
Menotropin is a purified extract of human postmenopausal gonadotrophin containing FSH and LH in a 1: 1 ratio.
Administration by subcutaneous or intramuscular injection.
Indicated to stimulate ovulation in assisted reproduction techniques.

Since the last update we have not found published data on its excretion in breastmilk.

Its high molecular weight makes it very unlikely it will transfer into milk in significant quantities.

Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.

No adverse effects have been recorded in infants.

In infertility treatments, the possible theoretical anovulatory effect of frequent on demand breastfeeding must be taken into account.


See below the information of these related products:

  • Assisted Reproductive Techniques (ART) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Follicle-stimulating Hormone (FSH) (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Lutropin Alfa (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for G03GA02.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

G03GA02 belongs to this group or family:

Tradenames

Main tradenames from several countries containing G03GA02 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 23.390 daltons
VD 1.08 l/Kg
Tmax 8 - 27 hours
13 hours

References

  1. AEMPS - Ferring. Menotropina (Menopur). Ficha técnica. 2015 Full text (in our servers)
  2. FDA-Ferring. Menotropin (Menopur). Drug Summary. 2014 Full text (in our servers)
  3. Ferring. Menotropin (Menopur). Drug Summary. 2008 Full text (in our servers)

Total visits

1,709

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM